A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Conditions: Cervical Cancer; Gastric Cancer (Including Stomach and Gastroesophageal Junction); Esophageal Cancer; Hepatocellular Carcinoma; Melanoma (Uveal Melanoma Excluded); Merkel Cell Carcinoma; Mesothelioma; Microsatellite Instability (MSI)-High/ Deficient Mismatch Repair ( dMMR) Tumors; Non-small Cell Lung Cancer (NSCLC); Ovarian Cancer; Squamous Cell Carcinoma of the Head and Neck; Small Cell Lung Cancer; Renal Cell Carcinoma (RCC); Triple-negative Breast Cancer; Urothelial Carcinoma Intervention: Drug: INCAGN02390 Sponsor: Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Gastric (Stomach) Cancer | Gastroenterology | Gastroschisis Repair | Mesothelioma | Non-Small Cell Lung Cancer | Study